04:49 AM EST, 01/28/2025 (MT Newswires) -- Drugs Made In America Acquisition (DMAA) said late Monday it priced an initial public offering of 20 million units at $10 each.

The company granted the underwriter a 45-day option to purchase up to an additional 3 million units.

Each unit consists of one ordinary share and one right to receive one-eighth of a share upon completion of an initial business combination, the blank-check company said.

Drugs Made In America Acquisition expects to close the IPO on Wednesday and its units are set to start Nasdaq trading under the ticker "DMAAU" starting Tuesday. Once the securities begin separate trading, the shares and rights are expected to be listed under the symbols "DMAA" and "DMAAR," respectively.